Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results.

Benucci M, Manfredi M, Saviola G, Sarzi-Puttini P, Atzeni F.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2):322-3. Epub 2013 Feb 1. No abstract available.

PMID:
23380047
2.

Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis.

Faillace C, de Carvalho JF.

Rheumatol Int. 2013 Jul;33(7):1909-10. doi: 10.1007/s00296-012-2409-1. Epub 2012 Mar 24. No abstract available.

PMID:
22441966
3.

Adalimumab arrests bone loss in the spine and hip of active rheumatoid arthritis patients with osteopenia.

Li H, Liu R, Chi S, Lu Z, Yang L.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1):134-5. Epub 2014 Dec 22. No abstract available.

PMID:
25536341
4.

Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.

Terenzi R, Santoboni G, Bartoloni E, Alunno A, Luccioli F, Gerli R.

Clin Exp Rheumatol. 2015 May-Jun;33(3):445. Epub 2015 Apr 28. No abstract available.

PMID:
25937244
5.

Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection.

Giannitti C, Fineschi I, Frediani B, Fioravanti A, Galeazzi M.

Clin Exp Rheumatol. 2013 Sep-Oct;31(5):816. Epub 2013 Sep 9. No abstract available.

PMID:
24021246
6.

Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection.

Nagashima T, Maruyama A, Kamata Y, Minota S.

Rheumatol Int. 2012 Jul;32(7):2231-2. doi: 10.1007/s00296-011-2060-2. Epub 2011 Jul 23. No abstract available.

PMID:
21785953
7.

Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.

Yokoe I, Nishio S, Sato H, Kobayashi H.

Mod Rheumatol. 2011 Dec;21(6):710-4. doi: 10.1007/s10165-011-0474-z. Epub 2011 Jun 8. No abstract available. Erratum in: Mod Rheumatol. 2012 Aug;22(4):643.

PMID:
21656090
8.

IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2012;70(3):195-9. Review.

9.

Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis.

Sandoo A, Panoulas VF, Toms TE, Smith JP, Stavropoulos-Kalinoglou A, Metsios GS, Gasparyan AY, Carroll D, Veldhuijzen van Zanten JJ, Kitas GD.

J Hum Hypertens. 2011 Nov;25(11):699-702. doi: 10.1038/jhh.2011.36. Epub 2011 Apr 28. No abstract available.

PMID:
21525886
10.

Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab.

Fusama M, Nakahara H, Hamano Y, Nishide M, Kawamoto K, Hosokawa T, Nozato S, Higa S, Igarashi T, Takeuchi E, Kuroiwa T, Shimaoka Y, Yukioka M, Miura Y, Higashi K, Kuritani T, Maeda K.

Mod Rheumatol. 2013 Mar;23(2):276-83. doi: 10.1007/s10165-012-0674-1. Epub 2012 Jun 6.

PMID:
22669600
11.

Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience.

Epis O, Casu C, Belloli L, Schito E, Filippini D, Muscarà M, Bruschi E.

Rheumatol Int. 2015 Sep;35(9):1569-70. doi: 10.1007/s00296-015-3243-z. Epub 2015 Mar 13. No abstract available.

PMID:
25773656
12.

Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab.

Hirao M, Yamasaki N, Oze H, Ebina K, Nampei A, Kawato Y, Shi K, Yoshikawa H, Nishimoto N, Hashimoto J.

Rheumatol Int. 2012 Dec;32(12):4041-5. doi: 10.1007/s00296-011-2135-0. Epub 2011 Sep 11.

13.

Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.

Suzuki T, Hirota T, Ogishima H, Umeda N, Kondo Y, Yokosawa M, Miki H, Tsuboi H, Matsumoto I, Sumida T.

Int J Rheum Dis. 2015 Jan;18(1):108-10. doi: 10.1111/1756-185X.12460. Epub 2014 Oct 7. No abstract available.

PMID:
25294091
14.

Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.

Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M, Laghi-Pasini F.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):332-9. doi: 10.1002/acr.22455.

15.

Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis.

Baker JF, Baker DG, Toedter G, Shults J, Von Feldt JM, Leonard MB.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):658-64. Epub 2012 Oct 17.

PMID:
22776409
16.

Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis.

Mori S.

Mod Rheumatol. 2012 Nov;22(6):947-50. doi: 10.1007/s10165-012-0593-1. Epub 2012 Feb 16. No abstract available.

PMID:
22350573
17.

Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.

Ajeganova S, Fiskesund R, de Faire U, Hafström I, Frostegård J.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):942-50. Epub 2011 Dec 22.

PMID:
22153361
18.

Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis.

Kume K, Amano K, Yamada S, Hatta K, Kuwaba N, Ohta H.

Arthritis Care Res (Hoboken). 2011 Oct;63(10):1477-81. doi: 10.1002/acr.20537.

19.

Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis.

Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, Atzeni F, De Gennaro Colonna V, Longhi M, Sarzi-Puttini P.

Cardiovasc Ther. 2010 Oct;28(5):e53-64. doi: 10.1111/j.1755-5922.2009.00119.x.

PMID:
20337633
20.

IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).

Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, Bay-Jensen AC, Platt A.

Semin Arthritis Rheum. 2012 Oct;42(2):131-9. doi: 10.1016/j.semarthrit.2012.01.004. Epub 2012 Mar 6.

PMID:
22397953
Items per page

Supplemental Content

Write to the Help Desk